The AChE inhibitor (−)-phenserine tartrate is a promising candidate as a treatment for Alzheimer’s disease and tritium labeling
of it was required for biological testing. This was accomplished by a halogenation, catalytic tritium dehalogenation strategy
resulting in a highly efficient incorporation of tritium. The position of tritium labeling was elucidated by a consideration
of both proton and tritium NMR spectra.